Tags

Type your tag names separated by a space and hit enter

Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis.
J Cardiovasc Pharmacol. 2008 Jan; 51(1):92-8.JC

Abstract

Carvedilol, a nonselective beta-blocker with additional alpha1-adrenergic blocking and antioxidant properties, has been shown to be cardioprotective in experimental myocarditis. However, the antioxidative effects of carvedilol have not been investigated in the setting of acute viral myocarditis. Therefore, this study investigated whether carvedilol protects against viral myocarditis primarily by its antioxidant and/or antiinflammatory properties. In a coxsackievirus B3 murine myocarditis model (Balb/c), effects of carvedilol and metoprolol on myocardial histopathological changes, cytokine levels, virus titers, malondialdehyde (MDA), and superoxide dismutase (SOD) contents were studied. Carvedilol markedly attenuated myocardial lesions and increased interferon-gamma and interleukin-12 production (cytokines) on day 7 with concomitant reduction of myocardial virus replication. In addition, only carvedilol decreased the content of MDA and increased the content of SOD on day 14. Metoprolol as well as bunazosin (a higly selective alpha1-adrenergic blocking agent) had no significant effects in this model. The results indicate that the superior protection of carvedilol in this model is probably the result of its antioxidative effects and the upregulation of antiinflammatory cytokines.

Authors+Show Affiliations

Department of Cardiology, Second Affiliated Hospital of Wenzhou Medical College, Wenzhou, China. heifeng1980@sina.com.cnNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

18209574

Citation

Yue-Chun, Li, et al. "Protective Effects of Carvedilol in Murine Model With the Coxsackievirus B3-induced Viral Myocarditis." Journal of Cardiovascular Pharmacology, vol. 51, no. 1, 2008, pp. 92-8.
Yue-Chun L, Li-Sha G, Jiang-Hua R, et al. Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. J Cardiovasc Pharmacol. 2008;51(1):92-8.
Yue-Chun, L., Li-Sha, G., Jiang-Hua, R., Peng-Lin, Y., Jia-Feng, L., Ji-Fei, T., Peng, C., & Zhan-Qiu, Y. (2008). Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. Journal of Cardiovascular Pharmacology, 51(1), 92-8. https://doi.org/10.1097/FJC.0b013e31815c6624
Yue-Chun L, et al. Protective Effects of Carvedilol in Murine Model With the Coxsackievirus B3-induced Viral Myocarditis. J Cardiovasc Pharmacol. 2008;51(1):92-8. PubMed PMID: 18209574.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. AU - Yue-Chun,Li, AU - Li-Sha,Ge, AU - Jiang-Hua,Ren, AU - Peng-Lin,Yang, AU - Jia-Feng,Lin, AU - Ji-Fei,Tang, AU - Peng,Chen, AU - Zhan-Qiu,Yang, PY - 2008/1/23/pubmed PY - 2008/4/4/medline PY - 2008/1/23/entrez SP - 92 EP - 8 JF - Journal of cardiovascular pharmacology JO - J Cardiovasc Pharmacol VL - 51 IS - 1 N2 - Carvedilol, a nonselective beta-blocker with additional alpha1-adrenergic blocking and antioxidant properties, has been shown to be cardioprotective in experimental myocarditis. However, the antioxidative effects of carvedilol have not been investigated in the setting of acute viral myocarditis. Therefore, this study investigated whether carvedilol protects against viral myocarditis primarily by its antioxidant and/or antiinflammatory properties. In a coxsackievirus B3 murine myocarditis model (Balb/c), effects of carvedilol and metoprolol on myocardial histopathological changes, cytokine levels, virus titers, malondialdehyde (MDA), and superoxide dismutase (SOD) contents were studied. Carvedilol markedly attenuated myocardial lesions and increased interferon-gamma and interleukin-12 production (cytokines) on day 7 with concomitant reduction of myocardial virus replication. In addition, only carvedilol decreased the content of MDA and increased the content of SOD on day 14. Metoprolol as well as bunazosin (a higly selective alpha1-adrenergic blocking agent) had no significant effects in this model. The results indicate that the superior protection of carvedilol in this model is probably the result of its antioxidative effects and the upregulation of antiinflammatory cytokines. SN - 0160-2446 UR - https://www.unboundmedicine.com/medline/citation/18209574/Protective_effects_of_carvedilol_in_murine_model_with_the_coxsackievirus_B3_induced_viral_myocarditis_ L2 - https://doi.org/10.1097/FJC.0b013e31815c6624 DB - PRIME DP - Unbound Medicine ER -